Topic: tumor

Turalio

18. Turalio

While Daiichi Sankyo previously worked on the BRAF inhibitor Zelboraf with Genentech, Turalio represents its first solo cancer drug—and one of seven that Daiichi Sankyo hopes to obtain approvals for by 2025.